Full-Time

Maintenance Tech Instrumentation & Electrical-3

Posted on 11/23/2025

Mallinckrodt

Mallinckrodt

1,001-5,000 employees

Specialty pharmaceutical developer, manufacturer, distributor

No salary listed

Raleigh, NC, USA

In Person

Category
Electrical Engineering (1)
Requirements
  • High School diploma, GED, or equivalent.
  • 1 – 3 years I/E experience in a pharmaceutical manufacturing operation.
  • Must have a working knowledge of the tools and test equipment used for testing, calibrating, repairing, and maintaining production instruments and controls.
  • Must be able to read and comprehend blueprints, electrical schematics, and engineering specifications.
  • Must be able to perform shop math.
  • Must be able to understand electricity, respect, and follow safety guidelines.
  • Must be able to read and follow written instruction.
  • Experience working with voltages up to 480.
  • Experience with CMMS, such as MP2 or Maximo.
Responsibilities
  • Installs, troubleshoots, repairs, and calibrates low voltage AC/DC electrical and instrumentation controls as well as 3-phase 480-volt power circuits.
  • Interfaces with OEM’s and vendors as necessary. Requisitions equipment as needed.
  • Accurately completes all work performed according to standard operating procedures (SOPs) and work instructions, including proper documentation. Completes work orders using CMMS (Maximo) system.
  • Performs repairs and modifications as directed by maintenance supervisor, or other plant management.
  • Supports and participates in training programs.
  • Keeps the maintenance supervisor abreast of job status.
  • Supports site safety programs.
  • Supports/leads failure analysis process by discussing the causes of equipment failure with the maintenance supervisor, or the maintenance engineer.
  • Accurately completes all required paperwork, including but not limited to timesheets, “found as-left” forms, calibration reports (ICIR), and PM checklists.
  • Responsible for good housekeeping in the shop and at the job site.
  • Other duties as assigned with or without accommodations.
  • Supports the PM/PdM program and calibration program by ensuring a high quality of workmanship.
  • Accurately enters all required information on work orders.
  • Assists the maintenance supervisor and maintenance engineers, or others as needed with equipment installation, maintenance, repair techniques, and with identifying opportunities for improving equipment reliability.
  • Shows emphasis on the design, installation, commissioning, maintenance, and use of mechanical equipment throughout the facility.
  • Recognizes problem independently and troubleshoots malfunctioning equipment without direct supervision.
Desired Qualifications
  • Associate or Technical degree in a mechanical field preferred.
  • Should be familiar with National Electrical Code, NFPA 70E, calibration standards, and cGMP.
  • Experience with PLCs is desirable.
  • Learning on the Fly, Problem Solving, Interpersonal Savvy

Mallinckrodt is a global specialty pharmaceutical company that develops, manufactures, and distributes drugs and therapies for complex and rare conditions, serving healthcare providers, hospitals, and patients mainly in the United States and Europe. Its products target areas such as autoimmune diseases, rare diseases, and critical care, and the business rests on research and development, manufacturing, and sales. The company differentiates itself through a patient-centric approach, a commitment to integrity, ongoing innovation, and collaboration, grounded in more than 150 years of experience and a focus on ESG initiatives. Its goal is to improve the health and well-being of patients worldwide by delivering specialty medicines and advancing sustainable practices.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Hazelwood, Missouri

Founded

1867

Simplify Jobs

Simplify's Take

What believers are saying

  • Merger with Endo completed, forming NYSE-listed therapeutics leader by Q4 2025.
  • Reduced debt 47% to $865.6M and grew Acthar Gel sales 14.2% in 2024.
  • Sold Therakos for $925M, optimizing portfolio for specialty pharmaceuticals.

What critics are saying

  • Endo merger integration disrupts operations, overloading with $6.7B debt.
  • Therakos sale drops immunotherapy revenue, losing edge to Amgen immediately.
  • Acthar Gel's $300K pricing triggers DOJ probe and $500M fines within 18 months.

What makes Mallinckrodt unique

  • Mallinckrodt specializes in Acthar Gel for autoimmune diseases over 150 years.
  • Focuses on rare diseases and critical care therapies for underserved patients.
  • Launched Acthar Gel self-injectable to improve patient adherence and convenience.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Mallinckrodt who can refer or advise you

Benefits

Performance Bonus

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
PR Newswire
Nov 10th, 2025
Par Health Completes Spin-Off from Mallinckrodt, Creating an Independent Leader in Generic Pharmaceuticals and Sterile Injectables

Launches as Top 15 U.S. Generic Drug Manufacturer, Largest U.S. Producer of Active Pharmaceutical Ingredients and Premier U.S. Producer of Sterile Injectables...

Contract Pharma
Aug 6th, 2025
Mallinckrodt Names Christiana Stamoulis President and CFO

Mallinckrodt plc appointed Christiana Stamoulis as President and Chief Financial Officer, effective September 22, 2025.

Stock Titan
Aug 1st, 2025
Mallinckrodt-Endo Merger Creates Therapeutics Leader

Mallinckrodt and Endo have completed a merger to form a global therapeutics leader. The companies will combine their generics businesses and Endo's sterile injectables business, which will be spun off as an independent company by Q4 2025. The newly branded company will be listed on the New York Stock Exchange following the spin-off.

The Business Journals
Jul 25th, 2025
Mallinckrodt Reaches $7B Merger Milestone

Mallinckrodt has reached a milestone in a $7 billion merger deal.

Sharecast
Mar 13th, 2025
Mallinckrodt and Endo to merge in $6.7bn deal

Pharmaceutical firm Mallinckrodt said on Thursday that it has agreed to merge with Endo in a $6.7bn deal.

INACTIVE